Remternetug · TRAILRUNNER-ALZ 3
This specific long-term progression trial is not the shorter amyloid-clearance TRAILRUNNER studies. The sponsor trial tables place its clinical assessment years away; no near-term readout is asserted. remternetug — phase 3 study in Alzheimer's Disease. NCT06653153 lists Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR) as a primary outcome (Baseline to Time to Event up to Week 255). Registry status: active not recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2029-04 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Long-horizon Alzheimer's study — date unconfirmed
Potential outcome market
Will remternetug meet the prespecified primary endpoint in NCT06653153 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.